Cosmetic Product Labelling in the European Union
The Regulation (EC) No 1223/2009 lays down the mandatory information that needs to be included in the packaging and container of a cosmetic products. In addition to this information, most cosmetic products include certain claims, which must be supported and properly substantiated.


A cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use.

According to the European Regulation on Cosmetic Products (Regulation (EC) No 1223/2009), before making available a cosmetic product on the market the Responsible Person (RP) shall notify the product in the Cosmetic Products Notification Portal (CPNP). (see previous posts on CPNP and RP)

The original labelling, and, where reasonably legible, a photograph of the corresponding packaging are two of the mandatory information that need to be notified by the RP.

Cosmetic products introduced in the EU market must indicate in their container and packaging (in indelible, easily legible and visible lettering) the following information:

  • Name and address of the RP
    • If several addresses are indicated, the one where the RP makes readily available the PIF shall be highlighted (see previous post)
  • Nominal content at the time packaging (weight or volume)
  • Date until which the cosmetic products, stored under appropriate conditions, will continue to fulfil its initial function and will remain safe for human health
    • ‘Date of minimum durability’ or ‘Period After Opening’ (PAO)
  • Particular precautions to be observed in use and any special precautionary information on cosmetic products for professional use
  • Batch number of manufacture or the reference for identifying the cosmetic product
  • Function of the cosmetic product (unless it is clear from its presentation)
  • List of ingredients in descending order of concentration, preceded by the term ‘ingredients

For imported cosmetic products, the country of origin also needs to be indicated in the label.


The majority of cosmetic products available on the market include claims on their label.

Claims can be in the form of texts, names, trademarks, pictures and figurative or other signs that convey explicitly or implicitly product characteristic or functions in the labelling, marketing and advertising of cosmetic products.

A cosmetic product cannot contain or imply false or irrelevant information and its claims should be supported by adequate and verifiable evidence (i.e., nothing should be claimed that cannot be supported). Overall, cosmetic products claims must be clear, true, objective, understandable and give enough information to allow consumers to make informed decisions. (see previous post)

Claims must be supported and properly substantiated, which means that the information provided must be proven. This proof may be obtained by researching the available literature, by experimental studies, by performing consumer perception tests or using all of the above. The decision on how to do it should be made in accordance with the nature of the product and type of claim.


Consumer demands are shaping the cosmetics industry and making it more sustainable and ‘eco-friendly’. Cosmetic companies are trying to adapt and we can see an increasing number of cosmetic products claiming to be ‘natural’, ‘environmental friendly’ and similar. But how can such claims be supported and properly substantiated?

For example, ISO 16128 provides guidelines on definitions and criteria for natural and organic cosmetic ingredients and products, specific to the cosmetics sector. Besides ISO 16128, the COSMOS and Natrue certifications have been used for cosmetic products and raw materials, and products compliant with these two are clearly labelled as such. The ISO standard may be used simultaneously with the other certifications and provides a worldwide unified criteria, but it does not work as a marketing claim (or label). (see previous post)

Nevertheless, more guidelines are needed when talking about clean, eco-friendly and sustainable products. These should cover responsible sourcing and stablish standards for higher degrees of transparency.

‘Free from’ claims are also a market trend and very much appreciated by consumers. Annex III of the Technical document on cosmetic claims (prepared by the Sub-Working Group on Claims) provides guidance for the application of the common criteria established by the Commission Regulation (EU) No 655/2013 to ‘free from’ claims. It includes illustrative and non-exhaustive examples of this type of claims, with the aim of helping the industry to correctly use them. (see previous post)

One example is the ‘free from parabens‘ claims, which should not be used. Certain parabens are safe when used according to the European Cosmetics Regulation, and the use of these type of claims is denigrating the entire group of parabens (authorized substances).

Not sure if your cosmetic product labelling is compliant with regulation? Need help on claims substantiation? Critical Catalyst can help! Feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Regulation (EU) No 655/2013 of 10 July 22013 laying down common criteria for the justification of claims used in relation to cosmetic products.
  3. ISO 16128-1:2016. Cosmetics — Guidelines on technical definitions and criteria for natural and organic cosmetic ingredients – Part 1: Definitions for ingredients.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »